Point-of-Care Tests for Hepatitis B Are Associated with A Higher Linkage to Care and Lower Cost Compared to Venepuncture Sampling During Outreach Screenings in an Asian Migrant Population.


Journal

Annals of global health
ISSN: 2214-9996
Titre abrégé: Ann Glob Health
Pays: United States
ID NLM: 101620864

Informations de publication

Date de publication:
16 07 2020
Historique:
entrez: 4 8 2020
pubmed: 4 8 2020
medline: 6 7 2021
Statut: epublish

Résumé

This study compares venepuncture versus point-of-care (POC) HBsAg tests on screening cost and linkage to care in prospective outreach screenings in an Asian population in three major cities in Belgium between 10/2014 and 5/2018. Two community outreach screening programs were organised between 10/2014 and 5/2018. The first screening program used venepuncture and serologic testing for HBsAg. In the second program, HBsAg was tested in finger stick blood POC tests. Positive results were confirmed during outpatient visits with serologic testing. Linkage to care was defined as having received specialist care follow-up with at least one abdominal ultrasound within three months of screening. For 575 participating individuals, 571 valid results were obtained, 456 with venepuncture, and 115 using POC testing. Overall HBsAg seroprevalence was 6.8%. Linkage to care was higher when using POC testing compared to venepuncture (86% or n = 6/7 versus 34% or n = 11/32; p = 0.020). The POC screening program was economically more attractive with a total cost of € 1,461.8 or € 12.7 per person screened compared to € 24,819 or € 54.0 per person screened when using venepuncture testing. Results and an appointment for specialist care follow-up were given onsite with POC testing, while with venepuncture testing; results were sent within 20-45 days. In an Asian migrant population in Belgium with an HBsAg seroprevalence of 6.8%, HBV screening based on POC tests resulted in lower costs per person screened (76.5% lower), and higher linkage to care (2.5 times).

Sections du résumé

Background
This study compares venepuncture versus point-of-care (POC) HBsAg tests on screening cost and linkage to care in prospective outreach screenings in an Asian population in three major cities in Belgium between 10/2014 and 5/2018.
Methods
Two community outreach screening programs were organised between 10/2014 and 5/2018. The first screening program used venepuncture and serologic testing for HBsAg. In the second program, HBsAg was tested in finger stick blood POC tests. Positive results were confirmed during outpatient visits with serologic testing. Linkage to care was defined as having received specialist care follow-up with at least one abdominal ultrasound within three months of screening.
Results
For 575 participating individuals, 571 valid results were obtained, 456 with venepuncture, and 115 using POC testing. Overall HBsAg seroprevalence was 6.8%. Linkage to care was higher when using POC testing compared to venepuncture (86% or n = 6/7 versus 34% or n = 11/32; p = 0.020). The POC screening program was economically more attractive with a total cost of € 1,461.8 or € 12.7 per person screened compared to € 24,819 or € 54.0 per person screened when using venepuncture testing. Results and an appointment for specialist care follow-up were given onsite with POC testing, while with venepuncture testing; results were sent within 20-45 days.
Conclusion
In an Asian migrant population in Belgium with an HBsAg seroprevalence of 6.8%, HBV screening based on POC tests resulted in lower costs per person screened (76.5% lower), and higher linkage to care (2.5 times).

Identifiants

pubmed: 32742939
doi: 10.5334/aogh.2848
pmc: PMC7366862
doi:

Substances chimiques

Hepatitis B Surface Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

81

Informations de copyright

Copyright: © 2020 The Author(s).

Déclaration de conflit d'intérêts

The authors have no competing interests to declare.

Références

BMC Infect Dis. 2016 Aug 15;16(1):415
pubmed: 27526685
J Infect Public Health. 2013 Dec;6(6):448-55
pubmed: 23999342
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
PLoS One. 2016 Mar 08;11(3):e0150176
pubmed: 26954020
Hepatology. 2015 Jul;62(1):87-100
pubmed: 25808668
J Hepatol. 2012 Dec;57(6):1171-6
pubmed: 22885717
Hepatol Int. 2014 Aug 01;8(4):478-92
pubmed: 25298848
J Epidemiol Glob Health. 2016 Dec;6(4):277-284
pubmed: 27373603
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Public Health Rep. 2016 May-Jun;131 Suppl 2:20-8
pubmed: 27168657
BMC Public Health. 2017 Sep 26;17(1):747
pubmed: 28950835
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
J Hepatol. 2013 Mar;58(3):473-8
pubmed: 23183527
BMC Infect Dis. 2013 Apr 18;13:181
pubmed: 23597411
Theor Biol Med Model. 2017 May 18;14(1):11
pubmed: 28521828
Hepatology. 1994 Jul;20(1 Pt 1):15-20
pubmed: 8020885
J Clin Virol. 2014 Jul;60(3):200-5
pubmed: 24794796
AIDS. 2012 Oct 23;26(16):2059-67
pubmed: 22781227
J Hepatol. 2013 May;58(5):890-7
pubmed: 23333446
J Clin Virol. 2015 Jul;68:79-82
pubmed: 26071342

Auteurs

Erwin Ho (E)

Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, BE.
Laboratory of Experimental Medicine and Paediatrics, University of Antwerp, Antwerp, BE.

Peter Michielsen (P)

Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, BE.
Laboratory of Experimental Medicine and Paediatrics, University of Antwerp, Antwerp, BE.

Pierre Van Damme (P)

VAXINFECTIO, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, BE.

Margareta Ieven (M)

VAXINFECTIO, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, BE.

Irene Veldhuijzen (I)

Division of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, Rotterdam, NL.

Thomas Vanwolleghem (T)

Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, BE.
Laboratory of Experimental Medicine and Paediatrics, University of Antwerp, Antwerp, BE.
Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, NL.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH